Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, New York, USA.
Cancer. 2012 Dec 1;118(23):5947-54. doi: 10.1002/cncr.27658. Epub 2012 Jun 15.
A subset of patients who present with metastatic solid tumors never receive anticancer therapy. Reasons may include poor functional status, comorbidities, and patient preference. To the authors' knowledge, the prevalence and characteristics of this population have not previously been described.
The National Cancer Data Base was queried for patients diagnosed with metastatic (stage IV according to the American Joint Committee on Cancer) solid tumors (including those of the breast, cervix, colon, and kidney; small cell and nonsmall cell lung cancer [NSCLC]; and tumors of the prostate, rectum, and uterus) who received neither radiotherapy nor systemic therapy. Log-binomial regression analysis was used to estimate prevalence ratios (PRs) for the percentage of untreated to treated patients with stage IV cancer.
Between 2000 and 2008, 773,233 patients with stage IV cancer were identified, 159,284 of whom (20.6%; 95% confidence interval, 20.5%-20.7%) received no anticancer therapy. Patients with NSCLC accounted for 55% of the untreated population. Patients with cancers of the kidney and lung had the highest rates of no treatment at 25.5% and 24.0%, respectively, whereas patients with prostate cancer had the lowest rate of no treatment at 11.1%. Across all cancer types, older age (PR range, 1.37-1.49; all P < .001), black race (PR range, 1.05-1.32; all P < .001), lack of medical insurance (PR range, 1.47-2.46; all P < .001), and lower income (except for cancer of the uterus; PR range, 0.91-0.98 for every $10,000-increase in income [all P < .001]) were associated with a lack of treatment.
Approximately 20% of patients who present with stage IV solid tumors do not receive anticancer therapy. Although there are likely multiple reasons for this lack of treatment, including appropriate indications, these findings have potential implications with regard to health care policy and access to care.
有一部分转移性实体瘤患者从未接受过抗癌治疗。原因可能包括功能状态差、合并症和患者偏好。据作者所知,这部分人群的患病率和特征尚未被描述。
本研究通过美国国家癌症数据库查询了诊断为转移性(根据美国癌症联合委员会分期为 IV 期)实体瘤(包括乳腺癌、宫颈癌、结肠癌和肾癌、小细胞肺癌和非小细胞肺癌以及前列腺癌、直肠癌和子宫癌)且未接受放疗或全身治疗的患者。使用对数二项式回归分析估计 IV 期癌症未治疗与治疗患者的百分比的患病率比(PR)。
在 2000 年至 2008 年期间,共发现 773233 例 IV 期癌症患者,其中 159284 例(20.6%;95%置信区间,20.5%-20.7%)未接受抗癌治疗。非小细胞肺癌患者占未治疗人群的 55%。肾癌和肺癌患者未治疗的比例最高,分别为 25.5%和 24.0%,而前列腺癌患者未治疗的比例最低,为 11.1%。在所有癌症类型中,年龄较大(PR 范围,1.37-1.49;所有 P <.001)、黑种人(PR 范围,1.05-1.32;所有 P <.001)、无医疗保险(PR 范围,1.47-2.46;所有 P <.001)和低收入(除子宫癌外;PR 范围,每增加 10000 美元收入,PR 为 0.91-0.98[所有 P <.001])与缺乏治疗相关。
约 20%的 IV 期实体瘤患者未接受抗癌治疗。尽管这种缺乏治疗的原因可能有很多,包括适当的适应证,但这些发现可能对医疗保健政策和获得治疗的机会产生影响。